Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

19.90USD
11:14am EDT
Change (% chg)

$-0.30 (-1.49%)
Prev Close
$20.20
Open
$20.00
Day's High
$20.20
Day's Low
$19.70
Volume
19,937
Avg. Vol
223,399
52-wk High
$25.70
52-wk Low
$12.45

Latest Key Developments (Source: Significant Developments)

Impax Launches Generic Version Of Estrace Cream
Friday, 6 Apr 2018 07:33am EDT 

April 6 (Reuters) - Impax Laboratories Inc ::IMPAX LAUNCHES A GENERIC VERSION OF ESTRACE® CREAM (ESTRADIOL VAGINAL CREAM, USP, 0.01%).IMPAX LABORATORIES INC - ‍LAUNCHED GENERIC VERSION OF ESTRACE CREAM​​.  Full Article

Impax Shareholders Approve Proposed Business Combination With Amneal
Tuesday, 27 Mar 2018 04:05pm EDT 

March 27 (Reuters) - Impax Laboratories Inc ::IMPAX SHAREHOLDERS APPROVE PROPOSED BUSINESS COMBINATION WITH AMNEAL.IMPAX LABORATORIES INC - AT MEETING, 51.8 MILLION SHARES, OR APPROXIMATELY 99% OF VOTES CAST, VOTED IN FAVOR OF BUSINESS COMBINATION.  Full Article

Amneal Gains Approval For Erythromycin Tablets USP
Wednesday, 14 Mar 2018 08:00am EDT 

March 14 (Reuters) - Impax Laboratories Inc ::AMNEAL GAINS APPROVAL FOR ERYTHROMYCIN TABLETS USP.AMNEAL PHARMACEUTICALS SAYS RECEIVED FDA APPROVAL FOR ERYTHROMYCIN TABLETS USP, 250 MG AND 500 MG STRENGTHS.  Full Article

Impax Reports Q4 Gaap Loss Per Share $4.18
Thursday, 1 Mar 2018 07:00am EST 

March 1 (Reuters) - Impax Laboratories Inc ::IMPAX REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.11.Q4 GAAP LOSS PER SHARE $4.18.Q4 REVENUE FELL 7.8 PERCENT TO $182.9 MILLION.  Full Article

Bora Pharmaceuticals buys pharma firm owned by Impax Laboratories for $18.5 mln
Tuesday, 6 Feb 2018 02:25am EST 

Feb 6 (Reuters) - Bora Pharmaceuticals Co Ltd <6472.TWO> ::Says it completed acquisition of 100 percent stake in a pharmaceutical company owned by Impax Laboratories,Inc for $18.5 million .  Full Article

Impax Announces Sale Of Taiwan Manufacturing Facility
Tuesday, 19 Dec 2017 08:45am EST 

Dec 19 (Reuters) - Impax Laboratories Inc ::IMPAX ANNOUNCES SALE OF TAIWAN MANUFACTURING FACILITY.IMPAX LABORATORIES INC - ‍ ENTERED INTO A DEFINITIVE AGREEMENT TO SELL IMPAX TAIWAN TO BORA PHARMACEUTICALS CO​.IMPAX LABORATORIES - BORA WILL PURCHASE ALL OF ISSUED SHARE CAPITAL IN IMPAX TAIWAN, CERTAIN LOANS OUTSTANDING BETWEEN CO, UNIT FOR $18.5 MILLION..IMPAX LABORATORIES INC - AS A RESULT OF SALE, CO EXPECTS TO RECORD A PRE-TAX IMPAIRMENT CHARGE OF ABOUT $70.0 TO $80.0 MILLION IN Q4 OF THIS YEAR.IMPAX LABORATORIES INC - ‍AS A RESULT OF SALE, CO EXPECTS TO RECORD PRE-TAX IMPAIRMENT CHARGE OF ABOUT $70.0 TO $80.0 MILLION IN Q4 OF THIS YEAR​.IMPAX LABORATORIES INC - ‍ BORA WILL HAVE RIGHTS TO MARKET AND SELL IMPAX'S BRANDED PARKINSON'S DRUG RYTARY IN TAIWAN​.IMPAX - ALSO SIGNED SUPPLY AGREEMENT WITH BORA, EFFECTIVE UPON CLOSING OF TRANSACTION.IMPAX SAYS SIGNED SUPPLY AGREEMENT WITH BORA TO MANUFACTURE, SUPPLY OF CERTAIN OF CO'S MARKETED, DEVELOPMENT PRODUCTS CURRENTLY MANUFACTURED BY UNIT.  Full Article

Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules
Friday, 8 Dec 2017 07:30am EST 

Dec 8 (Reuters) - Impax Laboratories Inc ::IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES.IMPAX LABORATORIES INC - COMPANY'S ANDA IS ELIGIBLE FOR FINAL APPROVAL UPON EXPIRATION OF MARKETING EXCLUSIVITY ON MAY 7, 2018.  Full Article

Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​
Tuesday, 21 Nov 2017 05:22pm EST 

Nov 21 (Reuters) - Impax Laboratories Inc :Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​.Impax Laboratories Inc - ‍also entered into amendment no. 1 with K2 Merger Sub Corporation & Amneal Pharmaceuticals Llc​.Impax Laboratories Inc - ‍in connection with closing, Holdco will be renamed Amneal Pharmaceuticals, Inc.​.Impax Laboratories - ‍in connection with pipe transaction, amneal desires to revise capital structure of new amneal to provide for class B-1 stock​.  Full Article

Impax Q3 adjusted earnings per share $0.23
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Impax Laboratories Inc :Impax reports third quarter 2017 results.Q3 adjusted earnings per share $0.23.Q3 GAAP loss per share $0.69.Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S.Q3 revenue $206.4 million versus I/B/E/S view $208.4 million.Impax Laboratories Inc - sees ‍2017 adjusted gross margins as a percent of total revenue are expected to be approximately 47%​.Impax Laboratories Inc - sees ‍full year 2017 adjusted net income per share of $0.60 to $0.65​.FY2017 earnings per share view $0.70 -- Thomson Reuters I/B/E/S.Impax Laboratories Inc - sees 2017 ‍capital expenditures of approximately $25 million to $30 million​.Impax Laboratories Inc - ‍company narrows full year 2017 guidance​.Impax Laboratories Inc - ‍"while our Q3 results were in line with our expectations, we continue to navigate challenging generic market environment"​.Impax Laboratories Inc - ‍currently expect to complete closure of our Middlesex, New Jersey packaging facility by end of 2017, ahead of schedule​.Impax Laboratories Inc - ‍"we are in late-stage negotiations for sale of our Taiwan manufacturing facility​".Impax Laboratories - ‍if successful in selling Taiwan facility by end of Q1 of 2018, co could realize anticipated cost savings by end of 2018​.  Full Article

Impax gets FDA approval for generic Renvela tablets
Monday, 23 Oct 2017 04:01pm EDT 

Oct 23 (Reuters) - Impax Laboratories Inc :Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg.Impax Laboratories Inc - ‍impax has immediately initiated commercialization activities for a generic version of Renvela​.Impax Laboratories Inc - ‍sales of generic renvela are expected to benefit company's financial results this year​.  Full Article

BRIEF-Impax Launches Generic Version Of Estrace Cream

* IMPAX LAUNCHES A GENERIC VERSION OF ESTRACE® CREAM (ESTRADIOL VAGINAL CREAM, USP, 0.01%)